Scholarlink

Purpose <p>To report the outcomes of anti-tumor necrosis factor alpha (anti-TNF-α) treatment in children with refractory non-infectious uveitis.</p> Methods <p>Retrospective chart review for all children aged ≤ 18 years, diagnosed to have non-infectious uveitis, treated with anti-TNF-α medications (Infliximab or Adalimumab) from Jan 2014 to Dec 2021 with at least 1-year follow-up after initiation of treatment at King Khaled Eye Specialists Hospital (KKESH).</p> Results <p>A total of 32 patients (61 eyes) were included in the study. Thirteen patients (40.6%) were males, and 19 patients (59.4%) were females. The mean age upon presentation was 9.8 ± 3.9 years. The mean duration of follow-ups was 7.6 ± 2.2 years. Persistent anterior uveitis activity was noted in 58 eyes (95.1%), uveitic macular edema in 5 eyes (8.2%), vitritis in 7 eyes (11.5%), and vasculitis in 4 eyes (6.6%). Thirty patients (93.8%) were prescribed adalimumab, and 2 patients (6.2%) were prescribed infliximab. The addition of anti-TNF-α has significantly improved anterior uveitis activity (<i>P</i> &lt; 0.001), the grade of anterior uveitis (<i>P</i> &lt; 0.001), vitritis (<i>P</i> = 0.007), the grade of vitritis (<i>P</i> = 0.017), and disc edema (<i>P</i> = 0.014). Over 5 years of follow-ups, oral prednisolone doses were significantly reduced from 10.4 ± 4.3&#xa0;mg in 25 children to full steroids sparing treatments (<i>P</i> &lt; 0.001). There were no cataracts developed after the initiation of anti-TNF-α over 5 years of follow-up, while 2 eyes developed uveitic glaucoma.</p> Conclusion <p>The addition of anti-TNF-α achieves better uveitis control in pediatric patients who are not well controlled on conventional immunosuppressive treatment. Timely addition of anti-TNF-α leads to a lower incidence of long-term complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of anti-TNF α therapy on refractory non-infectious pediatric uveitis in Saudi Arabia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月17日

查看全文
  • Abeer Aljahdali,
  • Abrar A. Alhawsawi,
  • Maram Alenazi,
  • Moustafa S. Magliyah,
  • Hassan Al-Dhibi

摘要

Purpose

To report the outcomes of anti-tumor necrosis factor alpha (anti-TNF-α) treatment in children with refractory non-infectious uveitis.

Methods

Retrospective chart review for all children aged ≤ 18 years, diagnosed to have non-infectious uveitis, treated with anti-TNF-α medications (Infliximab or Adalimumab) from Jan 2014 to Dec 2021 with at least 1-year follow-up after initiation of treatment at King Khaled Eye Specialists Hospital (KKESH).

Results

A total of 32 patients (61 eyes) were included in the study. Thirteen patients (40.6%) were males, and 19 patients (59.4%) were females. The mean age upon presentation was 9.8 ± 3.9 years. The mean duration of follow-ups was 7.6 ± 2.2 years. Persistent anterior uveitis activity was noted in 58 eyes (95.1%), uveitic macular edema in 5 eyes (8.2%), vitritis in 7 eyes (11.5%), and vasculitis in 4 eyes (6.6%). Thirty patients (93.8%) were prescribed adalimumab, and 2 patients (6.2%) were prescribed infliximab. The addition of anti-TNF-α has significantly improved anterior uveitis activity (P < 0.001), the grade of anterior uveitis (P < 0.001), vitritis (P = 0.007), the grade of vitritis (P = 0.017), and disc edema (P = 0.014). Over 5 years of follow-ups, oral prednisolone doses were significantly reduced from 10.4 ± 4.3 mg in 25 children to full steroids sparing treatments (P < 0.001). There were no cataracts developed after the initiation of anti-TNF-α over 5 years of follow-up, while 2 eyes developed uveitic glaucoma.

Conclusion

The addition of anti-TNF-α achieves better uveitis control in pediatric patients who are not well controlled on conventional immunosuppressive treatment. Timely addition of anti-TNF-α leads to a lower incidence of long-term complications.